康泰医学（300869）8月25日主力资金净流入1380.78万元

Core Viewpoint - 康泰医学 (300869) has shown a positive performance in both stock price and financial results, indicating potential growth opportunities in the market [1][3]. Financial Performance - As of the first quarter of 2025, 康泰医学 reported total revenue of 112 million yuan, representing a year-on-year increase of 12.77% [1]. - The net profit attributable to shareholders reached 16.44 million yuan, with a significant year-on-year growth of 277.67% [1]. - The company's non-recurring net profit was 13.77 million yuan, reflecting a remarkable increase of 515.19% year-on-year [1]. - Key financial ratios include a current ratio of 12.442, a quick ratio of 10.900, and a debt-to-asset ratio of 32.77% [1]. Stock Market Activity - On August 25, 2025, 康泰医学's stock closed at 18.68 yuan, up by 2.36%, with a turnover rate of 4.5% [1]. - The trading volume was 114,000 hands, with a total transaction amount of 211 million yuan [1]. - The net inflow of main funds was 13.81 million yuan, accounting for 6.53% of the transaction amount [1]. Company Background - 康泰医学系统 (秦皇岛)股份有限公司 was established in 1996 and is located in Qinhuangdao City, primarily engaged in other manufacturing industries [2]. - The company has a registered capital of 401.80 million yuan and a paid-in capital of 241.80 million yuan [2]. - The legal representative of the company is 胡坤 [2]. Investment and Intellectual Property - 康泰医学 has made investments in 6 companies and participated in 419 bidding projects [2]. - The company holds 68 trademark registrations and 618 patents, along with 104 administrative licenses [2].